Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 5/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 2/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | CA1 | P00915 | 3/20 | 0.32 |
| ▸ | CA12 | O43570 | 1/20 | 0.32 |
| ▸ | CA3 | P07451 | 1/20 | 0.32 |
| ▸ | AR | P10275 | 1/20 | 0.32 |
| ▸ | CA4 | P22748 | 1/20 | 0.32 |
| ▸ | CA6 | P23280 | 1/20 | 0.32 |
| ▸ | CA5A | P35218 | 1/20 | 0.32 |
| ▸ | CA7 | P43166 | 1/20 | 0.32 |
| ▸ | CA9 | Q16790 | 1/20 | 0.32 |
| ▸ | CA13 | Q8N1Q1 | 1/20 | 0.32 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.32 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4573895 | 1.00 | CA2 (0.35) | CA2GAAGRIN2BLMNAALDH1A1 | |
| SCHEMBL3303040 | 1.00 | CA2 (0.35) | CA2GAAGRIN2BLMNAALDH1A1 | |
| SCHEMBL4329539 | 1.00 | CA2 (0.35) | CA2GAAGRIN2BLMNAALDH1A1 | |
| SCHEMBL12315840 | 1.00 | CA2 (0.35) | CA2GAAGRIN2BLMNAALDH1A1 | |
| SCHEMBL12315839 | 0.76 | CA2 (0.37) | CA2GAALMNAALDH1A1CA1 | |
| SCHEMBL6092290 | 0.76 | CA2 (0.37) | CA2GAALMNAALDH1A1CA1 | |
| SCHEMBL18651228 | 0.75 | CA2 (0.34) | CA2LMNACA1CA12CA3 | |
| SCHEMBL4196353 | 0.75 | CA2 (0.54) | CA2LMNACA1CA12CA3 | |
| SCHEMBL13852709 | 0.75 | CA2 (0.54) | CA2LMNACA1CA12CA3 | |
| SCHEMBL12315845 | 0.75 | CA2 (0.54) | CA2LMNACA1CA12CA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2010061398-A1 | PROCESS FOR PREPARING DORZOLAMIDE HYDROCHLORIDE AND ITS INTERMEDIATE | SUVEN LIFE SCIENCES LIMITED (IN) | 2010-06-03 | — | — | WO | claimed |
| CN-103415524-B | Asymmetric reduction method | ZACH SYSTEM S.P.A. (IT) | 2015-11-25 | — | — | CN | disclosed |
| US-8927740-B2 | Asymmetric reduction process | ZACH SYSTEM S.P.A. (IT) | 2015-01-06 | — | — | US | disclosed |
| CN-103415524-A | Asymmetric reduction process | ZACH SYSTEM SPA | 2013-11-27 | — | — | CN | disclosed |
| WO-2010061398-A1 | PROCESS FOR PREPARING DORZOLAMIDE HYDROCHLORIDE AND ITS INTERMEDIATE | SUVEN LIFE SCIENCES LIMITED (IN) | 2010-06-03 | — | — | WO | disclosed |
| WO-2009144263-A2 | PROCESS FOR OBTAINING 4-HYDROXY-6-METHYL-5, 6-DIHYDRO-4H-THIENO [2,3-b] THIOPYRAN-7, 7-DIOXIDE AND ITS ENANTIOMERS, AND APPLICATIONS THEREOF | RAGACTIVES, S.L.U. (ES) | 2009-12-03 | — | — | WO | disclosed |
| EP-2128161-A1 | Process for obtaining 4-hydroxy-6-methyl-5,6-dihydro-4H-thieno[2,3-b]thiopyran-7,7-dioxide and its enantiomers, and applications thereof | Ragactives, S.L. (ES) | 2009-12-02 | — | — | EP | disclosed |
| EP-2128161-A1 | Process for obtaining 4-hydroxy-6-methyl-5,6-dihydro-4H-thieno[2,3-b]thiopyran-7,7-dioxide and its enantiomers, and applications thereof | Ragactives, S.L. (ES) | 2009-12-02 | — | — | EP | disclosed |
| EP-2128161-A1 | Process for obtaining 4-hydroxy-6-methyl-5,6-dihydro-4H-thieno[2,3-b]thiopyran-7,7-dioxide and its enantiomers, and applications thereof | Ragactives, S.L. (ES) | 2009-12-02 | — | — | EP | disclosed |
| US-20090137821-A1 | Method of making dorzolamide hydrochloride | KOVACS LASZLO ZSOLT | 2009-05-28 | — | — | US | disclosed |
| EP-1753769-A2 | METHOD OF MAKING DORZOLAMIDE HYDROCHLORIDE | TEVA Gyógyszergyár Zártkörüen Müködö Részvénytársaság (HU) | 2007-02-21 | — | — | EP | disclosed |
| US-20060155132-A1 | Method of making dorzolamide hydrochloride | TEVA PHARMACEUTICALS USA, INC. | 2006-07-13 | — | — | US | disclosed |
| WO-2006074230-A2 | METHOD OF MAKING DORZOLAMIDE HYDROCHLORIDE | TEVA GYÓGYSZERGYÁR ZÁRTKÖRÜEN MÜKÖDÖ RÉSZVÉNYTÁRSASÁG (HU) | 2006-07-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060155132-A1 | Method of making dorzolamide hydrochloride | CYP3A4, CYP3A43, CYP2C19 | CA2 2835/4885GAA 352/4885GRIN2B 2051/4885 |
| US-20090137821-A1 | Method of making dorzolamide hydrochloride | CYP3A4, CYP3A43, CYP2C19 | CA2 2835/4885GAA 352/4885GRIN2B 2051/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.